SIGA (SIGA) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants Diem Nguyen - CEO & DirectorDaniel Luckshire - EVP & CFOJyoti Prakash - Director Operator Good afternoon. Welcome to FIGA Technology Business Update Call. Before we turn the call over to FIGA management, please note that any forward looking statements made during this call are based on management's current expectations and observations and are subject to risks and uncertainties that could cause actual results to differ from the ...

SIGA (SIGA) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Speaker0 Good afternoon. Welcome to FIGA Technology Business Update Call. Before we turn the call over to FIGA management, please note that any forward looking statements made during this call are based on management's current expectations and observations and are subject to risks and uncertainties that could cause actual results to differ from the forward looking statements. SIGA does not undertake any obligation to update publicly any forward look ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended March 31, 2025 Or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ________ to ___________ Commission File No. 0-23047 SIGA Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware ...

Summary Financial Results Exhibit 99.1 SIGA Reports Financial Results for Three Months Ended March 31, 2025 NEW YORK, May 8, 2025 (GLOBENEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three months ended March 31, 2025. "SIGA has carried its momentum from 2024 into 2025, achieving steady progress on its key initiatives," stated Diem Nguyen, Chief Executive Officer. "In the first quarter, an international sale of a ...

Received $26 Million IV TPOXX Procurement Order from the U.S. Government in March$94 million in TPOXX Orders (to be Delivered to U.S. Strategic National Stockpile) outstanding as of March 31, 2025Corporate Update Conference Call Today at 4:30 PM ET NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three months ended March 31, 2025. “SIGA has carried its momentum from 2024 into 2025, ac ...

Siga Technologies Inc. (SIGA) closed the most recent trading day at $5.43, moving -1.63% from the previous trading session. The stock's performance was behind the S&P 500's daily gain of 0.63%. On the other hand, the Dow registered a gain of 0.21%, and the technology-centric Nasdaq increased by 1.52%.Shares of the company have appreciated by 0.36% over the course of the past month, outperforming the Medical sector's loss of 2.42% and the S&P 500's loss of 0.7%.Analysts and investors alike will be keeping a ...

NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, May 8, 2025. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer. A live webcast of the call will also be available on the Company's website at http://www.siga.com in the Investor Rel ...

In the latest trading session, Siga Technologies Inc. (SIGA) closed at $6.51, marking a +0.39% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.74%. Elsewhere, the Dow gained 0.05%, while the tech-heavy Nasdaq added 1.26%.The company's stock has climbed by 16.34% in the past month, exceeding the Medical sector's loss of 7.7% and the S&P 500's loss of 4.77%.The investment community will be paying close attention to the earnings performance of Siga Technologies Inc ...

Core Viewpoint - SIGA Technologies, Inc. announced a special cash dividend of $0.60 per share, marking the fourth consecutive year of such dividends, reflecting the company's strong balance sheet and confidence in future business prospects [1][2]. Company Overview - SIGA is a commercial-stage pharmaceutical company focused on developing innovative medicines for infectious diseases, particularly orthopoxviruses [2]. - The company's flagship product, TPOXX (tecovirimat), is an antiviral approved for treating smallpox and authorized for other related diseases in various regions including the U.S., Canada, Europe, the UK, and Japan [2]. Financial Management - The CEO emphasized the company's commitment to disciplined financial management and strategic execution to enhance long-term shareholder value [2].

Group 1 - Siga Technologies Inc. closed at $5.32, reflecting a -1.3% change from the previous day, underperforming compared to the S&P 500's loss of 0.23% [1] - Over the past month, Siga's shares have decreased by 5.27%, which is less severe than the Medical sector's decline of 10.2% and the S&P 500's drop of 12.13% [1] Group 2 - The Zacks Consensus Estimates for Siga's upcoming earnings project earnings of $0.13 per share and revenue of $184.36 million, indicating a significant decrease of -84.15% in earnings and an increase of +32.97% in revenue compared to the previous year [2] - Recent adjustments to analyst estimates for Siga are important as they reflect short-term business trends, with positive revisions indicating a favorable business outlook [3] Group 3 - The Zacks Rank system, which assesses estimate changes, currently ranks Siga Technologies Inc. at 4 (Sell), with a notable 89.6% decrease in the consensus EPS estimate over the last 30 days [5] - Siga is trading at a Forward P/E ratio of 41.46, significantly higher than the industry average of 14.68, suggesting that Siga is trading at a premium [6] Group 4 - The Medical - Drugs industry, which includes Siga Technologies Inc., has a Zacks Industry Rank of 82, placing it in the top 34% of over 250 industries [6] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1, highlighting the potential for better performance within the industry [7]